News
![Nasdaq-Tower_092614_B 2](https://pharmaphorum.com/wp-content/uploads/2019/08/Nasdaq-Tower_092614_B-2.jpg)
Inozyme plans $75m IPO as it heads for clinic with rare bone...
US biotech Inozyme Pharma is the latest to jump on to the IPO bandwagon, setting terms for a $75 million stock market launch, as the firm gears up for clinical trials of its lead drug for r